Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Part A: To evaluate the safety of HuMax-CD20 in patients with active rheumatoid arthritis. Part B: To evaluate the efficacy of HuMax-CD20 in patients with active rheumatoid arthritis using the American College of Rheumatology (ACR) Response Assessment and Disease Activity Score (DAS) at 12 to 24 weeks after initiation of treatment.
Inclusion criteria
- active rheumatoid arthritis